Today, we’ve announced the drug discovery experts who will lead the Drug Discovery Alliance.
Dr John Davis is the new Chief Scientific Officer at the Alzheimer’s Research UK Oxford Drug Discovery Institute.
To tackle these diseases we need to see research into a range of therapeutic approaches, giving us the best chance of finding effective treatments sooner.
We’re hearing in the news that a new treatment designed to slow Alzheimer’s has shown benefit in one of the final stages of testing in people. So what’s going on?
Clinical trials are crucial to understand whether a treatment could help people with Alzheimer’s disease. And that is exactly what scientists are now trying to do with Liraglutide.
The report shines a necessary spotlight on some of the challenges facing dementia research today.
The Alzheimer’s Research UK Drug Discovery Alliance is a £30m powerhouse of dementia treatment discovery at leading universities for dementia research.
2014 has seen huge strides in dementia research as our researchers worked tirelessly to uncover clues about how to diagnose, treat and prevent dementia.
One year since the G8 Dementia Summit, new investment and exciting initiatives are bringing us closer to a treatment for dementia.
A new analysis clinical trials has concluded that taking B vitamins doesn’t slow decline in memory and thinking and is unlikely to prevent Alzheimer’s disease.